A

Actinium Pharmaceuticals
D

ATNM

1.24000
USD
-0.04
(-3.13%)
Market Open
Volume
4,444
EPS
-1
Div Yield
-
P/E
-1
Market Cap
38,682,905
OverviewSignalsIdeasNews
Related Instruments
    ABBV
    ABBV
    0.400
    (0.23%)
    175.895 USD
    AMGN
    AMGN
    -2.28
    (-0.87%)
    261.53 USD
    BMY
    BMY
    -0.020
    (-0.03%)
    57.260 USD
    GSK
    GSK
    0.200
    (0.60%)
    33.795 USD
    JNJ
    JNJ
    -0.730
    (-0.51%)
    143.650 USD
    MRK
    MRK
    0.510
    (0.52%)
    98.610 USD
    PFE
    PFE
    -0.030
    (-0.11%)
    26.330 USD
    More
News

Title: Actinium Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.